Aspen Investment Management Inc trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,540 shares of the company’s stock after selling 967 shares during the period. Johnson & Johnson accounts for 1.9% of Aspen Investment Management Inc’s holdings, making the stock its 10th biggest position. Aspen Investment Management Inc’s holdings in Johnson & Johnson were worth $2,922,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Nordwand Advisors LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $785,273,000. Edmp Inc. boosted its stake in shares of Johnson & Johnson by 17,222.9% in the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after acquiring an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the last quarter. GQG Partners LLC boosted its stake in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after acquiring an additional 1,805,632 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Price Performance
NYSE:JNJ opened at $162.68 on Friday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The company has a quick ratio of 0.77, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $422.76 billion, a P/E ratio of 34.03, a P/E/G ratio of 2.78 and a beta of 0.53. The stock’s fifty day moving average is $158.33 and its two-hundred day moving average is $166.96.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. Johnson & Johnson’s payout ratio is 94.56%.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on JNJ. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Guggenheim began coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Finally, Credit Suisse Group boosted their price objective on Johnson & Johnson from $168.00 to $170.00 in a research note on Friday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
- An Opportunity To Buy Starbucks Is Knocking On The Door
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
